RS111888148 (RYR1): increased MH risk with AA genotype
Upload your raw genetic data once, we'll show you which variants you carry and what the research says.
Key takeaways
- This variant increases risk of malignant hyperthermia when exposed to certain anesthetics
- Homozygous AA carriers do not show increased risk with remimazolam
- The effect is strongest for the A allele compared to G
- Risk remains possible but lower than AG or AA
Key takeaways
- This variant increases risk of malignant hyperthermia when exposed to certain anesthetics
- Homozygous AA carriers do not show increased risk with remimazolam
- The effect is strongest for the A allele compared to G
- Risk remains possible but lower than AG or AA
What the research says Allele A is linked to higher risk of malignant hyperthermia than allele G [PMID 16917943]. Homozygous AA carriers do not show increased risk with remimazolam [PMID 42218780].
Reported associations Malignant Hyperthermia - allele A increases risk compared to G [PMID 16917943].
Evidence quality The evidence is based on clinical and pharmacogenomic associations with allele A increasing risk [PMID 16917943] and a case report confirming homozygous AA not linked to remimazolam [PMID 42218780]. No GWAS effect size reported.
Drug response and pharmacogenomics
- Desflurane - increased risk in AA genotype [PMID 42218780]
- Remimazolam - no increased risk in AA genotype [PMID 42218780] Last lifestyle considerations on file for this variant.
Frequently asked questions
What does rs111888148 mean?
It is a variant in the RYR1 gene that increases risk of malignant hyperthermia when exposed to certain anesthetics especially for AA carriers.
Is this variant linked to osteoporosis?
No, the evidence only relates it to MH and anesthesia safety not bone health.
Can I avoid RMIMALAZ?
Remimazolam does not increase risk in AA carriers according to clinical data.